Randy L Jirtle

Title: Randy L Jirtle: Innovator in Cancer Prognosis and Tumor Suppression

Introduction

Randy L Jirtle is a prominent inventor based in Durham, NC (US). He has made significant contributions to the field of cancer research, particularly in the areas of cancer prognosis and tumor suppression. With a total of 2 patents, his work has the potential to impact diagnostic and therapeutic approaches in oncology.

Latest Patents

Randy L Jirtle's latest patents include innovative methods related to cancer prognosis. One of his notable inventions is titled "Cancer prognosis with the M6P/IGF-II receptor." This invention focuses on assessing the prognosis of a patient using the M6P/IGF-II receptor. Another significant patent is the "M6P/IGF-II receptor tumor suppressor gene," which relates to the mannose 6-phosphate/insulin-like growth factor-II (M6P/IGF-II) receptor and its applications in diagnostics and therapy.

Career Highlights

Throughout his career, Randy has worked with esteemed institutions such as Duke University and Zeneca Limited. His research has contributed to advancements in understanding cancer mechanisms and developing new therapeutic strategies.

Collaborations

Randy has collaborated with notable colleagues, including J Keith Killian and Timothy A Jamieson. These partnerships have further enriched his research and innovation in the field of cancer prognosis and treatment.

Conclusion

Randy L Jirtle's contributions to cancer research through his patents and collaborations highlight his role as an innovator in the field. His work continues to pave the way for advancements in cancer prognosis and therapeutic approaches.